Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy


Kister I., Spelman T., Patti F., Duquette P., Trojano M., Izquierdo G., ...More

JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.391, pp.72-76, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 391
  • Publication Date: 2018
  • Doi Number: 10.1016/j.jns.2018.06.001
  • Journal Name: JOURNAL OF THE NEUROLOGICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.72-76
  • Keywords: Multiple sclerosis, Relapse, Disability, Disease modifying therapy, Observational cohort study, MULTIPLE-SCLEROSIS, FINGOLIMOD TREATMENT, NATALIZUMAB, WITHDRAWAL, CESSATION, COHORT
  • Karadeniz Technical University Affiliated: Yes

Abstract

Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed disability progression (CDP) in a diverse group of patients exposed to different DMTs.